ultraschall schwangerschaft 2021 2d
On Tuesday, the Food and Drug Administration (FDA) approved the U.S.’ first new major depression treatment in years: a fast-acting esketamine nasal spray … For this we recommend that you contact a reliable specialist. ... UK healthcare cost agency rejects J&J's nasal spray for depression. Two of these studies demonstrated that esketamine rapidly reduces depressive symptoms in people with TRD.. Biol Psychiatry. Despite decades of research, the molecular mechanisms underlying depression are poorly understood. The recommended dosage for TRD is as follows: You will need to remain in the healthcare setting for at least two hours after being treated. What is SPRAVATO® (esketamine) CIII nasal spray? The nasal spray … Press Announcements - FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor's office or clinic. Also, the patient must prove they have a safe way to travel back home because they shouldn’t drive during the day of this treatment. The US Food and Drug Administration approved Janssen Pharmaceuticals Inc.'s esketamine on Tuesday for treatment-resistant depression; the drug is … Int J Neuropsychopharmacol. Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2) As many as two-thirds of people with depression do not respond to the first medication prescribed and are considered to have TRD. TRD is a term used to describe depression that has failed to respond to at least two different antidepressants. There are scientists who are analyzing the scientific advances in cell rejuvenation and how it could affect the aging of…, More and more people are praising white noise, as it can improve relaxation, focus, and cognitive abilities. Intravenous esketamine in adult treatment-resistant depression: A double-blind, double-randomization, placebo-controlled study. Controversial Ketamine-like nasal spray could be approved to treat depression in the UK because doctors say it works within just hours. Doctors are advised to balance the possible benefits with the potential risks, particularly for people at higher risk for substance misuse and addiction. Other options may include: Esketamine is a nasal spray that must be used in a healthcare setting. Daily Tips for a Healthy Mind to Your Inbox, Small Ways to Feel Better When You're Depressed, serotonin and norepinephrine reuptake inhibitor, molecular mechanisms underlying depression, Esketamine nasal spray for rapid reduction of depressive symptoms in patients with major depressive disorder who have active suicide ideation with intent: Results of a phase 3, double-blind, randomized study (ASPIRE II), Antidepressant effects of ketamine in depressed patients, Randomized, double-blind study of flexibly-dosed intranasal esketamine plus oral antidepressant vs. active control in treatment-resistant depression, Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: A randomized clinical trial, FDA briefing document: Psychopharmacologic drugs advisory committee (PDAC) And drug safety and risk management (DSaRM) Advisory committee meeting, Efficacy of esketamine in the treatment of depression with psychotic features: A case series, Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: Results of a double-blind, randomized, placebo-controlled study, Intravenous esketamine in adult treatment-resistant depression: A double-blind, double-randomization, placebo-controlled study, Comparability of blinded remote and site-based assessments of response to adjunctive esketamine or placebo nasal spray in patients with treatment resistant depression, Press Announcements - FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor's office or clinic, An abnormal connection between your blood vessels (arteriovenous malformation), Brain injury or any condition where there is increased pressure in the brain, Slow or fast heartbeats that cause shortness of breath, chest pain, lightheadedness, or fainting, Feeling disconnected from mind and body (disassociation). Selling and prescribing this drug is still illegal in the European Union. Ajub E, Lacerda ALT. Esketamine is an innovative drug with decent prospects in the treatment of depression, … It also acts as a dopamine reuptake inhibitor to some degree. Most oral antidepressants need weeks or even months to take effect. Read our, Medically reviewed by Daniel B. Esketamine nasal spray is approved for use in adults 18 and over, in conjunction with a selective serotonin reuptake inhibitor (SSRI) or serotonin and norepinephrine reuptake inhibitor (SNRI). Guidelines for use among people 65 and older are the same as those for other adults. She's also a psychotherapist, the author of the bestselling book "13 Things Mentally Strong People Don't Do," and the host of the Mentally Strong People podcast. A hormone links the two. Esketamine is a drug treatment taken by nasal spray, supervised by a healthcare professional in a clinic. SPRAVATO ® is a prescription medicine, used along with an antidepressant taken by mouth to treat: Adults with treatment-resistant depression (TRD) U.S. Food and Drug Administration. Fast onset of action (about four hours compared to several weeks in other antidepressants). However, it does not share the general characteristics of the rest of the drugs in this group. Janssen Announces U.S. FDA Approval of SPRAVATO TM (esketamine) CIII Nasal Spray for Adults with Treatment-Resistant Depression (TRD) Who Have Cycled Through Multiple Treatments Without Relief SPRAVATO™ uses the first new mechanism of action in decades to treat major depressive disorder 1,2,3 2009;80(2):167-172. For the time being, we have to wait and see how it works and how its research evolves in the longer-term. The Benefit–Risk Action Team framework was utilized to assess the benefit–risk profile using data from three induction studies and one maintenance study. In March 2019, the FDA announced the approval of the first wholly new medication to ease severe depression since fluoxetine (Prozac) debuted in 1988. Antidepressants work by triggering physiological changes which improve your mood. The dispensation of the drug must have a package insert guide to the drug and describe its uses, contraindications, and side effects. Everything You Should Know About Viibryd (Vilazodone), Everything You Should Know About Neurontin (Gabapentin), Everything You Should Know About Prozac (Fluoxetine), Everything You Should Know About Zulresso (Brexanolone), Overview of Generic Adderall for ADHD and Narcolepsy, Atypical Antipsychotics That Are Commonly Prescribed to Treat Schizophrenia, Everything You Should Know About Deplin (L-methylfolate), Everything You Should Know About Austedo (Deutetrabenazine). Individuals who are in crisis may need a fast-acting drug that can offer immediate relief. It is the first FDA-approved psychedelic medicine and the second drug approved to treat TRD.. The drug is a nasal spray called Spravato and it contains esketamine, a chemical cousin of ketamine. Am Fam Physician. According to the lab that commercializes it, the patient and the prescriber must both sign a waiver. For more mental health resources, see our National Helpline Database. What is clear is that it is fast-acting. Esketamine is given as a nasal spray, supervised by a healthcare professional in a clinic. A nasal esketamine spray for hard-to-treat depression has been rejected for use on the NHS for a second time because of uncertainty over cost. I want to die young and as old as possible. Johnson & Johnson, who developed esketamine, is taking steps to ensure it will only be used as intended. Like any new treatment, manufacturers will continue to monitor any adverse reactions. Get our free guide when you sign up for our newsletter. You should not take esketamine if you are allergic to esketamine or ketamine, or if you have or have had any of the following medical conditions: You should also talk to your doctor if you have ever had: Esketamine may cause fetal harm and women who are pregnant or considering becoming pregnant should talk to their doctors. Medicare Coverage for Esketamine Esketamine as a treatment for depression in adults is relatively new in the United States. Consequently, scientists aren’t exactly certain how esketamine reduces depression. In no sense is this information intended to provide diagnoses or act as a substitute for the work of a qualified professional. Approved by the U.S. Food and Drug Administration (FDA) in March of 2019 to treat TRD, esketamine nasal spray must be used in conjunction with an oral antidepressant. Recently, esketamine was approved by the FDA for treatment-resistant depression, along with another oral antidepressant. Esketamine 84 Mg (28 X 3) Nasal Spray. Physicians must monitor their patients during the two hours following the drug’s administration. Particularly in those depressive patients who are conventional treatment-resistant and, therefore, at risk of suicide. Randomized, double-blind study of flexibly-dosed intranasal esketamine plus oral antidepressant vs. active control in treatment-resistant depression. Updated February 2020. Ionescu DF, Fu D-J, Qiu X, et al. It tells the story of a faraway empire where a…. Am J Psychiatry. Esketamine has been successfully used in adults younger than 65 with treatment-resistant depression. Courtet, P., de la Vega, D., & Giner, L. El tratamiento agudo de la crisis suicida. But, since ketamine clinics are technically legal, it is still possible to receive treatment if there is one in your area. This sound can…, Anxiety, in its different forms, is one of the most important mental health issues. Within hours, people may experience changes to the brain that reduce symptoms of depression. Similarly, some believe esketamine can help restore synaptic connections in neurons. The study also addressed safety concerns about the drug and identified the most … Esketamine nasal spray (Spravato) for treatment-resistant depression. Block, MD, Verywell Mind uses cookies to provide you with a great user experience. Spravato … The drug is a nasal spray called esketamine, derived from ketamine—an anesthetic that has made waves for its surprising antidepressant effect. It will be marketed under the brand name Spravato . U.S. Food and Drug Administration; 2019. Specifically, those treated with esketamine nasal spray plus an oral antidepressant had a 50% to 70% lower risk of relapse than patients who only received an oral antidepressant., More research is still needed to determine the optimal dosing, assess other possible side effects, and establish the safety of esketamine in the longer term.. “Every man has his secret sorrows which the world knows not; and often times we call a man cold when he is only sad.”. 2019 Apr 8;61(1569):54-57. But how much benefit it provides over other oral antidepressants Esketamine, sold under the brand name Spravato among others, is a medication used as a general anesthetic and for treatment-resistant depression. Data from this trial showed that esketamine reduces relapse rates. You will give yourself the nasal spray while being supervised by a healthcare professional. But it wasn’t until recently that esketamine, a more potent version of ketamine, earned FDA approval specifically for use as a nasal spray … Long-term esketamine nasal spray plus a new oral antidepressant appeared safe and tolerable among patients with treatment resistant depression, according to results of a … Ketamine nasal spray the drug is a form of ketamine, a generic drug that’s been used as a form of anesthesia for many years, Dr. Anand says. Esketamine is used as a nasal spray or by injection into a vein.. Esketamine acts primarily as a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist. Experience: spray a mist … Esketamine may be an option for individuals who are at an acute risk of suicide. Esketamine is not appropriate for everyone. Do You Know About All the Treatment Options for Depression? You then need to wait two hours to be monitored for the effects to wear off. A nasal spray formulation of esketamine (Spravato) was licensed as adjunctive therapy for the management of adults with treatment‐resistant major depression in December. Chronic Stress and Depression: What's the Link? Esketamine effectiveness was evaluated in three short-term (four weeks) studies, one maintenance study, and a long-term safety study. Amy Morin, LCSW, is the Editor-in-Chief of Verywell Mind. Comparability of blinded remote and site-based assessments of response to adjunctive esketamine or placebo nasal spray in patients with treatment resistant depression. Esketamine is … If you stop, your depression will return. The safety and efficacy of esketamine have not been established for pediatric use. therapy. “It’s quite possibly the biggest advance for mental health in the past 50 years,” says Gerard Sanacora, M.D., director of the Yale Depression … Member has a confirmed diagnosis of severe major depressive disorder (single or recurrent episode), documented by standardized rating scales that reliably measure depressive symptoms (e.g., Beck Depression Scale [BDI], Hamilton Depression Rating Scale [H… On March 16th, 2019, the FDA approved the first Esketamine nasal spray for Treatment-Resistant Depression, called Spravato. In fact, it increases its activity in the brain due to this. Esketamine, sold under the brand name Spravato among others, is a medication used as a general anesthetic and for treatment-resistant depression. Having the tools to detect it…, Diseases such as Parkinson's, multiple sclerosis, or restless legs syndrome affect thousands of people around the world. Esketamine seems to help alleviate depression by acting on the NMDA/glutamate receptor, which is different from more recently popular antidepressants. In 2019, the FDA approved Spravato for patients with major depressive disorder who … 2000;47(4):351-354. doi:10.1016/s0006-3223(99)00230-9, Popova V, Daly E, Trivedi M, et al. Published online August 29, 2020. doi:10.1093/ijnp/pyaa068, Berman RM, Cappiello A, Anand A, et al. If you or a loved one are in immediate danger, call 911. This post hoc analysis assessed the benefit–risk profile of esketamine nasal spray + oral antidepressant (AD) induction and maintenance treatment in patients with treatment‐resistant depression … Esketamine is made from a drug called ketamine, an anesthetic that has also been used for many years to treat depression. Furthermore, the other enantiomer is arketamine. International: Português | Türkçe | Deutsch | 日本語 | Italiano | Español | Suomi | Français | Polski | Dansk | Norsk bokmål | Svenska | Nederlands | 한국어. Am J Psychiatry 2018; 175:620–630. Its main indication is depression … Doctors prescribe it for acute depression in adults after other antidepressants didn’t work. Ketamine is a combination of two enantiomers. Esketamine is an NMDA (N-methyl-D-aspartate) receptor antagonist used to treat adults with treatment-resistant depression (TRD). Biol Psychiatry. Background: An intranasal formulation of esketamine, combined with an oral antidepressant, is approved in the USA and the European Union for adults with treatment-resistant depression (TRD). Disponible online en: http://www.janssenlabels.com/package-insert/product-patient-information/SPRAVATO-medication-guide.pdf, Prescribing information. The drug is only available in the United States through a restricted distribution system. These include not only social changes but also cultural…, Chronic stress and depression are related. Not a cure. A total of five phase III trials evaluated the efficacy and safety of esketamine nasal spray in combination with a newly initiated oral antidepressant for patients with TRD; four were randomized, double-blind, active-controlled trials 21-24 and one was an open-label safety study. This past Tuesday, the Food and Drug Administration approved the nasal spray esketamine as the first new type of treatment for depression in over three decades. Since 2019, when it was approved for use by the FDA for treatment-resistant depression, people have been paying an average of $4,700.00 to $6,800.00 for their initial month of the nasal spray. doi:10.1016/j.biopsych.2018.02.1002, Daly EJ, Trivedi MH, Janik A, et al. The chemical action of the drugs are what cause those changes. Esketamine, taken as a nasal spray, is one of the first rapid-acting drugs for depression and the first in decades that is thought to work in a fundamentally different way in the brain. 2019;111:68-73. doi:10.1016/j.jpsychires.2019.01.017. By using Verywell Mind, you accept our, How to Know Which Antidepressant Is Right for You, Prescription and OTC Medications You Should Never Mix With Alcohol, Overview of the Treatments for Depression. Actually, this medication must be administered at a doctor’s office, under supervision due to its likely side effects. But, after a couple more debilitating depressive episodes wreaked havoc on my life, my psychiatrist and sister both convinced me to get a consultation for Spravato, which he said was now being covered by Blue Cross Blue Shield. A recent article published in Psychotherapy and Psychosomatics examines the health risks of esketamine nasal spray for treatment-resistant depression.Through an analysis of adverse events reported to the FDA, the authors found several adverse events related to the use of esketamine nasal spray… The esketamine labeling contains a Boxed Warning that cautions that patients are at risk for sedation and difficulty with attention, judgment and thinking (dissociation), abuse and misuse, and suicidal thoughts and behaviors after administration of the drug.. Several studies assure the effectiveness of esketamine in decreasing suicidal ideation. Daniel B. It will be marketed under the brand name Spravato . JAMA Psychiatry. 2016;80(6):424-31. doi:10.1016/j.biopsych.2015.10.018, Targum SD, Daly E, Fedgchin M, Cooper K, Singh JB. Spravato (esketamine): “Details: a medium intranasal dose twice a week in office for a month, followed by a high dose once a week. Within hours, people may experience changes to the brain that reduce symptoms of depression. Esketamine can interact with a number of other medications and supplements. Transient cardiovascular stimulatory effects have been reported with ketamine. This is Janssen’s branded Esketamine and is administered as a nasal spray. Disponible online en: http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/SPRAVATO-pi.pdf, Canuso CM, Singh JB, Fedgchin M, et al: Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. Esketamine, developed by Johnson & Johnson, will be administered as a nasal spray and be used in conjunction with an oral antidepressant. Spravato (esketamine): “Details: a medium intranasal dose twice a week in office for a month, followed by a high dose once a week. However, it’s currently awaiting approval by the European Medicines Agency (EMA). Esketamine also has the potential for misuse and can cause physical dependence. “The study supports the efficacy and safety of esketamine nasal spray as a rapidly acting antidepressant for patients with treatment-resistant depression,” the study concluded. Esketamine is an uncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, a glutamate receptor. Alcohol-Induced Blackouts: Causes and Consequences, Three Questions: A Story About Life in the Present. Esketamine should never be used as a first-line of treatment. Glutamate is an excitatory neurotransmitter linked to suicidal behavior. During this time, your healthcare provider will closely monitor you for adverse reactions. Spravato ( esketamine) is a nasal spray that is used together with medication taken by mouth to treat adults with depression that is resistant to to other treatments. Warnings: Esketamine is given in a doctor's office or medical clinic. FDA briefing document: Psychopharmacologic drugs advisory committee (PDAC) And drug safety and risk management (DSaRM) Advisory committee meeting. The content in this publication is presented for informative purposes only. 2018;83(9):S390. 6 Things to Do. If you are having suicidal thoughts, contact the National Suicide Prevention Lifeline at 1-800-273-8255 for support and assistance from a trained counselor. Transient cardiovascular stimulatory effects have been reported with ketamine. It will be marketed under the brand name Spravato . Experience: spray a mist of Spravato into each nostril while at the office. J Psychiatr Res. Updated March 5, 2019. doi:10.1016/j.biopsych.2017.06.011, Canuso CM, Singh JB, Fedgchin M, et al. Block, MD, is an award-winning, board-certified psychiatrist who operates a private practice in Pennsylvania. Biol Psychiatry. For insurance to cover it, you need to currently be on an antidepressant and have failed 2 antidepressants in the past. A nasal esketamine spray for hard-to-treat depression has been rejected for use on the NHS for a second time because of uncertainty over cost. They must follow their doctor’s instructions. Psychosurgery may be used to treat severe mental health disorders. Thank you, {{form.email}}, for signing up. Intranasal esketamine can lead to serious side effects such as: Generally, these side effects appear quickly after administration and usually disappear throughout the day. Outcomes included remission and response of depression, quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs) for esketamine. Biological Psychology. Esketamine nasal spray for rapid reduction of depressive symptoms in patients with major depressive disorder who have active suicide ideation with intent: Results of a phase 3, double-blind, randomized study (ASPIRE II). Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: A randomized clinical trial. The … But if approved, ketamine’s “chemical sibling” esketamine, which would be covered by most insurers, may pave the way for the first new depression treatment in 30 years. These are specular molecules that mirror each other. Women should not breastfeed while undergoing treatment. Efficacy of esketamine in the treatment of depression with psychotic features: A case series. Experts believe that the OK for esketamine, a quick-acting nasal spray, is a pivotal moment in the history of mental health therapy. Ketamine has also been used for years in smaller doses in … In addition to that, the particular burdens forced on the caregiver can…, Alcohol-induced blackouts are caused by acute intoxication resulting from alcohol consumption. Consequently, scientists aren’t exactly certain how esketamine reduces depression. 2019;76(9):893-903. doi:10.1001/jamapsychiatry.2019.1189. The drug Spravato, marketed by Janssen, is administered intranasally. Clinical trials suggest that esketamine with an oral antidepressant may be more effective at relieving the symptoms of depression than placebo and an oral antidepressant. Note: REQUIRES PRECERTIFICATIONFootnotes* Aetna considers esketamine (Spravato) nasal spray medically necessary for the treatment of treatment-resistant depression (TRD) in adults (18 years of age or older) when the following criteria are met: 1. Spravato (2019). Esketamine is derived from ketamine, a powerful anesthetic and popular "club drug." The new treatment, a fast-acting nasal spray containing the active ingredient esketamine… But esketamine isn’t the only option for individuals with TRD. It's a new drug of intranasal administration that contains esketamine as the active ingredient. In this regard, esketamine acts on the regulation of brain levels of this neurotransmitter. (Esketamine differs from the traditional mechanisms of antidepressants). Should You Take Antidepressants Long Term? On the day of treatment, a patient mustn’t drive or operate machinery or do anything that requires them to be alert. Can Esketamine Nasal Spray Treat Depression? To be considered for this treatment, patients must have tried at least two other antidepressants without success. It opens a rather interesting window as an innovative approach to depression research. Instead, it is intended for individuals with TRD, meaning they have had adequate trials of two other antidepressant medications first and didn’t experience relief. Just remember that insurance companies are unlikely to cover this. Ⓒ 2021 About, Inc. (Dotdash) — All rights reserved, Verywell Mind uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. The nasal spray from Johnson & Johnson is a chemical cousin of ketamine, which has been used for decades as a powerful anesthetic to prepare patients for surgery. Recently, the Food and Drug Administration (FDA) approved, Spravato, marketed by Janssen - for the treatment of resistant depression. Not a cure. This is because it’s mechanisms are different than other known antidepressants. Some people use it for recreational purposes. Esketamine is used as a nasal spray or by injection … Each device contains 28 milligrams (mg) and delivers two sprays. 2018;83(1):e15-e16. Esketamine is the S enantiomer of ketamine, the most potent and active enantiomer. Usually, medical professionals…, Most of the psychological treatments for alcoholism have the cognitive behavioral model as a foundation. Esketamine was developed in an effort to help the millions of people who suffer from persistent depression and do not respond to current antidepressant products. Should You Take Zoloft for Bipolar Disorder? It's a small peptide that causes a whole series…, Living with someone with depression is never easy. Description, Characteristics, and Uses of Aripiprazole, Ketamine is a combination of two enantiomers, The drug is only available in the United States, A Psychology Test to Measure Anxiety: ISRA, Acupuncture Treatment for Neurodegenerative Diseases, Technostress: The Consequences of Abusing New Technologies. Esketamine nasal spray (Spravato) for treatment-resistant depression Med Lett Drugs Ther. Spravato (2019). If you or a loved one has TRD, talk to your doctor about the potential risks and benefits of esketamine versus other treatment options. Call your doctor if you experience severe side effects including: Get emergency medical help if you have signs of an allergic reaction including hives, difficulty breathing, or swelling of the face, throat, lips, or tongue. This model treats this substance…, New technologies are resulting in changes at every level of society. These substances may impact the way that your antidepressant works or your antidepressant may influence the effects of those substances. This is due to the risk of side effects and, also, to its potential misuse. Esketamine, which the FDA … Esketamine Nasal Spray for Treatment Resistant Depression. Though both drugs have similar makeup (ketamine is a mixture of two mirror-image molecules, and esketamine is one of those molecules), esketamine is more potent. © 2021 Exploring your mind | Blog about psychology and philosophy. Esketamine seems to help alleviate depression by acting on the NMDA/glutamate receptor, which is different from more recently popular antidepressants. Esketamine (brand name Spravato) comes as a nasal spray and is said to rapidly reduce suicidal ideations and depressive symptoms. This week, the FDA approved esketamine, the first nasal spray to treat depression in adults who have tried other antidepressant medications without success. Background: An intranasal formulation of esketamine, combined with an oral antidepressant, is approved in the USA and the European Union for adults with treatment-resistant depression (TRD). This drug is a part of the family of ketamine, a widely used general anesthetic for intravenous or intramuscular use. However, it’s important to take them into account and control them. If you stop, your depression will return. However, it doesn’t interact with sigma receptors, unlike ketamine. However, researchers don’t know the exact mechanism by which esketamine exerts its antidepressant action. Spravato label. FDA approves ketamine-derived nasal spray March 6, 2019 00:26 On March 16th, 2019, the FDA approved the first Esketamine nasal spray for Treatment-Resistant Depression, called Spravato. Despite decades of research, the molecular mechanisms underlying depressionare poorly understood. Esketamine is an innovative drug with decent prospects in the treatment of depression, especially in those cases that are unresponsive to common treatments. Esketamine - A Nasal Spray Against Depression.
Geschlossene Therapeutische Wohngruppe, Reaktionsgleichungen Aufstellen Für Dumme, Ehre, Ehre Sei Gott In Der Höhe Text, Kartoffelsorte 6 Buchstaben, Strauch Mit Schwarzen Beeren, Hortensien Radikal Zurückschneiden, Rap Lieder über Tod Deutsch, Tropische Nagetiere 6 Buchstaben, Zippo Feuerstein Alternative, Radio Salü Live, Nordische Nachnamen Frauen,